Proarrhythmic potential of reverse use-dependent drugs

Journal of Electrocardiology

Volumn 40, Issue 5, 2007, Pages 432-433

  Gussak, Ihor ^a,b   Litwin, Jeffrey ^a   Morganroth, Joel ^a,c  

^a eResearchTechnology   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEPRIDIL; LIDOCAINE; SOTALOL;

ANTIARRHYTHMIC ACTIVITY; BRADYCARDIA; CARDIOTOXICITY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DISEASE; HEART RATE; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; HUMAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROPHYLAXIS; QT PROLONGATION; STABLE ANGINA PECTORIS; TORSADE DES POINTES;

ANTI-ARRHYTHMIA AGENTS; BEPRIDIL; BRADYCARDIA; HUMANS; LONG QT SYNDROME; POTASSIUM CHANNEL BLOCKERS; RISK ASSESSMENT; RISK FACTORS;

EID: 34548185110     PISSN: 00220736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jelectrocard.2007.03.243     Document Type: Editorial

References (6)

1. Sadanaga T., and Ogawa T. Bepridil produces prominent bradycardia-dependent QT prolongation in patients with structural heart disease. J Electrocardiol 40 (2007) 428
2. Kahan T., and Bergfeldt L. Left ventricular hypertrophy in hypertension: its arrhythmogenic potential. Heart 91 (2005) 250
3. Antzelevitch C., and Belardinelli L. The role of sodium channel current in modulating transmural dispersion of repolarization and arrhythmogenesis. J Cardiovasc Electrophysiol 17 Suppl 1 (2006) S79-S85
4. Batchvarov V.N., Ghuran A., Smetana A., et al. QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol 282 (2002) H2356-H2363
5. Lipicky R.J. Cardiac safety of noncardiac drugs: historical recollections. In: Morganroth J., and Gussak I. (Eds). Cardiac safety of noncardiac drugs (2003), Humana Press, Totowa, New Jersey 3-12
6. Hondeghem L.M., and Snyders D.J. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 81 (1990) 686